In today’s briefing:
- ImmuneOnco(1541 HK): No Near Term Triggers, Commercialization Still Far Away, Placement Unattractive
- Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended
- Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended
- DWTX: Licenses SP16 for Treatment of Cancer Related Pain
ImmuneOnco(1541 HK): No Near Term Triggers, Commercialization Still Far Away, Placement Unattractive
- ImmuneOnco Biopharmaceuticals (Shanghai) (IOB HK) announced the placement of 24.2M shares for subscription at HK$14.5 per share.
- The company intends to use most of the net proceeds for further research and development of drug candidates IMM01, IMM2510 and IMM27M.
- The current market price of the stock makes the placement offer unattractive. Concerns remain with no drugs commercialized yet and the only possible commercialization expected to happen not before 2027.
Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended
- Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended, suggesting a potential benefit to patients while being treated the study is designed to examine whether an increased number of Hemopurifier treatments can help extend positive patient responses.
- The company’s goal is to build its database supporting development of the Hemopurifier as an oncology treatment and this data appears to support that goal.
- It will be important to monitor whether these observations are reproducible as the study progresses, as it is early in the clinical trial to draw definitive conclusions and the data from Cohort 1 is not statistically significant.
Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended
- Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended, suggesting a potential benefit to patients while being treated the study is designed to examine whether an increased number of Hemopurifier treatments can help extend positive patient responses.
- The company’s goal is to build its database supporting development of the Hemopurifier as an oncology treatment and this data appears to support that goal.
- It will be important to monitor whether these observations are reproducible as the study progresses, as it is early in the clinical trial to draw definitive conclusions and the data from Cohort 1 is not statistically significant.
DWTX: Licenses SP16 for Treatment of Cancer Related Pain
- On September 29, 2025, Dogwood Therapeutics, Inc. announced it had secured a worldwide, royalty free license to develop SP16 for the treatment of cancer related pain and chemotherapy induced neuropathy symptoms from Serpin Pharma.
- A Phase 1b study of SP16 in Chemotherapy Induced Peripheral Neuropathy (CIPN) that is fully funded by the National Cancer Institute is scheduled to begin patient enrollment in the first half of 2026.
- This deal expands Dogwood’s research pipeline and complements the ongoing development of Halneuron , which is currently in a Phase 2b clinical trial for Chemotherapy Induced Neuropathic Pain (CINP).
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
